Euroapi S.A. EAPI

• A 5-year manufacturing contract to support the FOCUS-27 project sales trajectory
  
  
• This contract highlights EUROAPI’s know-how and the reliability of its premium Contract Manufacturing Organization services to customers
  
  

Paris – May 23, 2024 – EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAPI will supply its client with a key veterinary product. The total contract value is expected to range between €130 and 150 million, over the 2025-2029 period.

“The conclusion of this major contract secures the long-term supply of a complex chemical molecule, crucial for veterinary use. This is a true recognition of EUROAPI’s know-how and of the reliability of the premium service we offer to our customers,” said Ludwig de Mot, Chief Executive Officer of EUROAPI. “This agreement will be a key driver of our FOCUS-27 project sales trajectory.”

EUROAPI has a strong expertise within the animal health sector with many customers and products in its portfolio such as hormones, prostaglandins and complex synthesis molecules. The value of the global animal health market has been estimated at $41.8 billion in 2023 and is expected to reach $56.8 billion by 2030, at a CAGR of 4.5%¹.

About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.

Forward-Looking Statements
Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group’s current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 “Risk factors” of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 5, 2024. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based.

1 Source: https://healthforanimals.org/ and company estimates.

Attachment

• EUROAPI - Press release - May 23, 2024